111.94
0.01%
-0.01
前日終値:
$111.95
開ける:
$112.88
24時間の取引高:
4.43M
Relative Volume:
1.06
時価総額:
$498.76B
収益:
$37.42B
当期純損益:
$13.05B
株価収益率:
46.49
EPS:
2.4077
ネットキャッシュフロー:
$9.51B
1週間 パフォーマンス:
-1.27%
1か月 パフォーマンス:
-5.14%
6か月 パフォーマンス:
-13.37%
1年 パフォーマンス:
+14.60%
Novo Nordisk Adr Stock (NVO) Company Profile
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-30 | 開始されました | Goldman | Buy |
2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
2024-01-23 | 開始されました | Morgan Stanley | Overweight |
2024-01-16 | 再開されました | UBS | Neutral |
2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-02 | 開始されました | Argus | Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-06-28 | ダウングレード | UBS | Neutral → Sell |
2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
2022-01-25 | ダウングレード | Liberum | Hold → Sell |
2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
2021-01-15 | 開始されました | Deutsche Bank | Buy |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
2020-05-11 | ダウングレード | UBS | Buy → Neutral |
2020-05-04 | 開始されました | Cowen | Market Perform |
2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
2018-12-11 | 再開されました | Jefferies | Hold |
2018-10-09 | 開始されました | Guggenheim | Buy |
2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - Benzinga
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail
NVO: 3 European Stocks to Buy as the Region Recovers - StockNews.com
NVO’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Market cap of Novo Nordisk ADR [NVO] reaches 391.26B – now what? - The DBT News
Analyzing Novo Nordisk ADR (NVO) After Recent Trading Activity - Knox Daily
Monitoring Melco Resorts & Entertainment Ltd ADR (MLCO) after recent insider movements - Knox Daily
Weekly Upgrades and Downgrades - InvestorPlace
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 — Data Talk - Morningstar
Novo Nordisk ADR (NVO) receives a Buy rating from Goldman - Knox Daily
The Attractiveness of Investing In Tenaris S.A. ADR (TS) is Growing - Knox Daily
Stock Market Recap: Novo Nordisk ADR (NVO) Concludes at 118.01, a -0.89 Surge/Decline - The Dwinnex
Banco Santander S.A. ADR [SAN] Investment Appeal on the Rise - Knox Daily
Analyzing Indonesia Energy Corp Ltd (INDO) After Recent Trading Activity - Knox Daily
CNH Industrial NV [CNH] Investment Guide: What You Need to Know - Knox Daily
Company’s Banking Stock: Dissecting a -17.46% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novo Nordisk ADR (NVO) Stock: A Year of Decreases and Increases - The InvestChronicle
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales - Investor's Business Daily
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Eli Lilly Stock: Is LLY Stock A Buy After Snagging Approval For A New Eczema Drug? - Investor's Business Daily
Analysts review Novo Nordisk ADR’s rating - Knox Daily
Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Balance Sheet Insights: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Novo Nordisk ADR (NVO) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug - Investor's Business Daily
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):